Abrdn PLC Nektar Therapeutics Transaction History

Abrdn PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 18, 2020	SELL	$15.87 - $23.12 $875,833 - $1.28 Million	-55,188 Reduced 83.07%	11,246 $243,000
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $1.42 Million - $3.04 Million	-83,947 Reduced 55.82%	66,434 $1.21 Million
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $1.98 Million - $2.31 Million	-63,740 Reduced 29.77%	150,381 $5.35 Million
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $325,084 - $477,126	-10,294 Reduced 4.59%	214,121 $7.2 Million
Q4 2018 Feb 12, 2019	BUY	$30.43 - $56.65 $1.9 Million - $3.54 Million	62,404 Added 38.52%	224,415 $7.44 Million

Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $5.25 Million - $7.74 Million	113,029 Added 230.76%	162,011 $9.88 Million
Q2 2018 Aug 09, 2018	BUY	$46.25 - $104.45 $424,436 - $958,537	9,177 Added 23.05%	48,982 $2.39 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $1.47 Million - $2.77 Million	25,559 Added 179.41%	39,805 $4.23 Million
Q4 2017 Feb 12, 2018	SELL	$23.02 - $60.5 $161,140 - $423,500	-7,000 Reduced 32.95%	14,246 $851,000
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $377,966 - $509,904	21,246	21,246 $510,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

Stay updated on Abrdn PLC with notifications on news.